All issues
Volume 12, Issue 1
Displaying 1-6 of 6 articles from this issue
- |<
- <
- 1
- >
- >|
-
Fumimaro TAKAKU1971 Volume 12 Issue 1 Pages 1-12
Published: 1971
Released on J-STAGE: October 31, 2008
JOURNAL RESTRICTED ACCESSDownload PDF (1016K)
-
Masami HIRANO, Moriji MIURA, Hisami KAKIZAWA, Fujio SAKO, Akimitsu MOR ...1971 Volume 12 Issue 1 Pages 13-20
Published: 1971
Released on J-STAGE: October 31, 2008
JOURNAL RESTRICTED ACCESSNew sulfonic acid esters of aminoglycols, N-methyl-bis (3-mesyloxypropyl) amine hydrochloride (No. 838) and bis (3-mesyloxypropyl) amine hydrochloride (No. 864) have been used for the treatment of leukemias and malignant lymphomas with the following results.
Both agents were markedly effective in chronic myelogenous leukemia; No. 838, given in a daily dose of 0.5 mg/kg i.v., induced complete remissions in all 15 cases treated (total dose ranging from 135 to 1,000 mg with a median of 500 mg). No. 864, being somewhat less myelosuppressive, produced complete remissions in 8 of 9 patients (in 11 of 13 treatment courses). The total dose given ranged from 800 to 1,700 mg with a median of 1,100 mg.
In 6 patients with acute leukemia in whom No. 838 was used for the induction of remission it became evident that the drug decreases the “total leukemic cell mass” very effectively. However, only 1 out of 6 patients obtained a partial remission. The agent successfully relilved excruciating bone aches in 2 patients with acute phase of chronic myelogenous leukemia.
Among 4 patients with malignant lymphoma treated with No. 838, one showed a good response. Further studies are necessary to evaluate the effectiveness of these new alkylating agents in the treatment of acute leukemia and malignant lymphoma. Search for the optimal method for the administration of these agents should also be carried out.View full abstractDownload PDF (681K) -
Michiko TAKIKAWA, Yoshiko NOGUCHI, Michiko KANAKI, Toshio UEDA, Miwa M ...1971 Volume 12 Issue 1 Pages 21-28
Published: 1971
Released on J-STAGE: October 31, 2008
JOURNAL RESTRICTED ACCESSThree cases in a family of hereditary spherocytosis were reported. The chromosome analysis was performed on two hundred and thirty cells in the patient's bone marrow. Of these, 91% showed normal diploidy, and 9% polyploidy, unusually high incidence for normal individuals.
Clinical data from fifty-seven patients of thirty-six families, which appeared in Japanese literatures from 1962 through 1969, were summarized. There was no sex difference in incidence among the patients. Their first visit to hospitals were under 30 years of age and anemia was not outstanding. In rare cases MCT was normal. Apparent half-life of the autologous erythrocytes was about 10 days. Jaundice was generally mild. Fifty-two per cent of patients had history of familial transmission of hereditary spherocytosis.View full abstractDownload PDF (655K)
-
Yoshiyuki HANAWA, Toru ISE, Shusuke MATSUYAMA, Shyoichiro SHIKE, Ryo K ...1971 Volume 12 Issue 1 Pages 29-37
Published: 1971
Released on J-STAGE: October 31, 2008
JOURNAL RESTRICTED ACCESSSixteen children with acute leukemia and four children with malignant lymphoma have been treated by L-asparaginase. All the cases had been treated before with one or more of the conventional chemotherapeutic agents. The dosage of L-asparaginase ranged from 100 to 250 u/kg daily for 5 to 15 days. In 12 among 20 cases steroid hormones were administered simultaneously combined with L-asparaginase.
Of the acute leukemia patients, the overall remission rate was 25%. After the induction of remission, L-asparaginase was discontinued. For the maintenance therapy, one or more agents among 6-MP, methotrexate, cyclophosphamide and prednisolone were administered. The median duration of remission was two and a half months with a range of one to four months.
In four cases of malignant lymphoma, no clinical improvements were observed.
The following signs of toxicity have been observed: fever (two cases), nausea and vomiting (four cases), skin rash (two cases), abnormal liver function tests (GOT, five cases and GPT, six cases).View full abstractDownload PDF (683K) -
Hisomu YAMAGUCHI, Kazuo CHIBA, Tatsuya MOTOKI, Shiro MIWA, Toshihiro N ...1971 Volume 12 Issue 1 Pages 38-43
Published: 1971
Released on J-STAGE: October 31, 2008
JOURNAL RESTRICTED ACCESSA 28-year-old woman, dressmaker, was first seen on November 6, 1969, because of anemia, jaundice and palpitation on exertion. Her parents are first cousins, but other family history is non-contributory. At the age of 21 years she was noticed to be anemic and jaundiced. On admission on March 14, 1970, she was pale with mild jaundice. Liver and spleen were palpable a fingerbreadth below the costal margin.
On examination hemoglobin was 8.4 Gm. per cent, red cell count 2.25 million per cu. mm., hematocrit 26.5%, reticulocytes 8.9%, white cell count 3,700 with normal differential, and platelets 183,000 per cu. mm. MCD was 8.08 μ and osmotic fragility of the red cells was within normal limits. Apparent half-life of the autologous erythrocytes measured by 51Cr was 15.0 days. Direct antiglobulin test was negative. Marked erythroid hyperplasia was noticed in the sternal marrow aspirate. Serum bilirubin was 4.4 mg per cer cent with indirect type 3.6 mg per cent. Estimated weight of the spleen with 203Hg-MHP was 320 Gm.
Among the estimated red cell enzymes the level or pyruvate kinase decreased to 1.72 μM/min./1010 RBC (normal 4.55±0.69). The estimation of red cell glycolytic intermediates and adenine nucleotides revealed the increase in PEP, 2-PG, 2, 3-DPG and 3-PG and the decrease in lactate formation.
A diagnosis of pyruvate kinase deficiency was made and the patient has been followed without specific treatment. There has been no change in her conditions.
Her eldest brother was examined on August 29, 1970, and no abnormality was found; the level of the erythrocyte pyruvate kinase was 5.64 μM/min./1010 RBC.View full abstractDownload PDF (634K) -
Takaomi MINEDA, Tomoharu TAKAKU, Hiroaki FUKANO, Haruyasu KONDO, Tsune ...1971 Volume 12 Issue 1 Pages 44-49
Published: 1971
Released on J-STAGE: October 31, 2008
JOURNAL RESTRICTED ACCESSIn 14 children with leukemia, two patients were observed to have meningeal involvement in the past four years from 1966 through 1969.
One of them was treated with intrathecal administration of Methotrexate to induce complete relief. Meningeal involvement of leukemia was increased in the course of prolonged survival of patients under reasonable therapy, being invited at their remissional as well as aggravative conditions. This complication has seemingly increased recently and caused various neurologic signs or symptoms, of which. the most common signs were nausea, vomiting, headache and convulsion through increased cerebrospinal fluid pressure.View full abstractDownload PDF (693K)
- |<
- <
- 1
- >
- >|